UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________ Form 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______to_______ Commission file number 001-34045 _________________________ ENOVIS CORPORATION (Exact name of registrant as specified in its charter ...

Enovis Announces Fourth Quarter and Full Year 2023 Results • Continued strong momentum with fourth-quarter sales growth of 11%, organic growth of 8% • Reported a fourth-quarter net income from continuing operations of $0.05 per share with adjusted earnings per diluted share of $0.79 • Entering 2024 with strong operating momentum and an exciting slate of new product launches WILMINGTON, DE, February 22, 2024 (GLOBE NEWSWIRE)—Enovis™ Corporation (NYSE: ENOV), an innovation-driven medical technology growth com ...

WILMINGTON, DE, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE:ENOV), an innovation-driven, medical technology company, will showcase its latest technologies across the orthopedic care continuum at the American Academy of Orthopedic Surgeons Annual Meeting 2024. In addition, the Company will present itself as a newly integrated company following the acquisition of orthopedic leader LimaCorporate S.p.A ("Lima"). "Enovis has a lot to be excited about in 2024. In our Surgical business, the additio ...

WILMINGTON, DE, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Today, Enovis™ Corporation (NYSE:ENOV), an innovation-driven medical technology company, announced it will showcase the latest technologies from its Global Foot and Ankle business at the American College of Foot & Ankle (ACFAS) annual meeting in Tampa, Fla., from February 1-4, 2024. The company will feature products from its recent acquisitions of Novastep® and the external fixation assets of D.N.E., LLC, along with the internally developed Evolve34™ Lapidus ...

威爾明頓，特拉華州, Jan. 04, 2024 (GLOBE NEWSWIRE) -- 創新驅動的醫療技術成長型公司 Enovis™ Corporation （NYSE: ENOV，以下簡稱「Enovis」或「公司」）今日宣布已完成對 LimaCorporate S.p.A （以下簡稱「Lima」）的收購。Lima 是一家私人控股的全球骨科領先企業，專注於透過創新的植入解決方案組合恢復運動功能。 Lima 憑藉成熟的手術解決方案和技術的互補性產品組合，鞏固了 Enovis 在全球骨科重建市場的地位，這將加速公司的全球增長和利潤擴張。此外，Lima 的產品組合包括 3D 打印 Trabecular Titanium 植入物和全面的肩部修復產品，這將進一步加強該公司在快速成長的四肢市場中的地位。 「我們很高興歡迎 Lima 的優秀團隊加入 Enovis。此次合併使 Enovis 的重建分部收入達到 10 億美元，並成為全球骨科重建市場快速成長的創新者。這是我們如何利用策略性收購來加速成長、為公司增添優秀技術和人才、以及為股東帶來複合價值的又一範例。」Enovis 董事長兼行政總裁 Matt Trerotol ...

And certainly, in the quarter, the 7% is more like in the neighborhood of market growth versus the above-market rate growth. It is normal. But then if you stack it on top of 17% last year, then you'd see kind of 2 years of comfortably above market growth. You mentioned pricing. Some of your larger peers are talking about getting better pricing sessions in an inflationary environment. Are you seeing that as well? And also in terms of gross margin, you did see some improvements. How much of that is related to ...

Enovis Corporation (NYSE:ENOV) Q2 2023 Earnings Conference Call August 3, 2023 8:30 AM ET Company Participants Derek Leckow - Vice President of Investor Relations Matt Trerotola - Chief Executive Officer Ben Berry - Chief Financial Officer Conference Call Participants Vik Chopra - Wells Fargo Brett Fishbin - KeyBanc Kyle Rose - Canaccord Genuity Vijay Kumar - Evercore ISI Dane Reinhardt - Baird Operator Good day, and welcome to the Enovis Second Quarter 2023 Earnings Call. [Operator Instructions] Please not ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT ☒ OF 1934 For the quarterly period ended June 30, 2023 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT ☐ OF 1934 For the transition period from to Commission File Number: 001-34045 Enovis Corporation (Exact name of registrant as specified in its charter) Delaware 54-1887631 (State or other jurisdiction of (I.R.S. ...

Enovis Corporation (NYSE:ENOV) Q1 2023 Results Conference Call May 4, 2023 8:30 AM ET Company Participants Derek Leckow - Vice President of Investor Relations Matt Trerotola - Chief Executive Officer Ben Berry - Chief Financial Officer Conference Call Participants Vik Chopra - Wells Fargo Kyle Rose - Canaccord Genuity Jeff Johnson - Baird Xuyang Li - Jefferies Brett Fishbin - KeyBanc Operator Good day, and welcome to the Enovis First Quarter 2023 Earnings Conference Call [Operator Instructions]. Please note ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT ☒ OF 1934 For the quarterly period ended March 31, 2023 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT ☐ OF 1934 For the transition period from to Commission File Number: 001-34045 Enovis Corporation (Exact name of registrant as specified in its charter) Delaware 54-1887631 (State or other jurisdiction of (I.R.S. ...